Scholar Rock Announces the Addition of Joshua Reed to Its Board of Directors
March 18 2021 - 4:05PM
Business Wire
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical
company focused on the treatment of serious diseases in which
protein growth factors play a fundamental role, today announced
that Joshua Reed has been appointed to Scholar Rock’s Board of
Directors as an independent director. Mr. Reed is a highly
accomplished leader in the biopharmaceutical industry with over two
decades of experience in financial operations, strategic planning,
and investment banking. He will serve as chair of the audit
committee on Scholar Rock’s Board.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210318005940/en/
Joshua Reed (Photo: Business Wire)
“We are delighted to build upon the breadth of expertise by
welcoming Joshua to Scholar Rock’s Board of Directors,” said David
Hallal, Chairman of the Board of Scholar Rock. “Scholar Rock is at
an important juncture in its evolution and Joshua brings an
essential operational and strategic perspective from clinical and
commercial stage companies that will be invaluable to the company’s
next phase of growth.”
“I am thrilled to be joining the Scholar Rock Board and working
alongside the team to build and advance the company through a
number of potentially transformative milestones,” said Mr. Reed.
“Scholar Rock is on the path to revolutionizing the treatment
paradigm for patients affected by a wide range of serious diseases,
including spinal muscular atrophy and cancer, and I am excited to
be part of this journey towards achieving their goal of
meaningfully improving the lives of patients.”
Mr. Reed joined Aldeyra Therapeutics as Chief Financial Officer
in 2018 and is responsible for the finance, compliance, information
technology, human resources, and facilities functions. Prior to
Aldeyra, he held roles of increasing responsibility at
Bristol-Myers Squibb (BMS), including supply chain finance,
operations finance, financial planning and analysis, mergers and
acquisitions, and most recently as the Vice President and Head of
Finance for the company’s United States and Puerto Rico Operations.
Before joining BMS, Mr. Reed served as Vice President, Strategic
Business Development at JPMorgan Chase and worked in investment
banking at Credit Suisse First Boston. Mr. Reed received a B.S. in
Finance from Rutgers University and an MBA from the University of
Michigan’s Ross School of Business.
About Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company
focused on the discovery and development of innovative medicines
for the treatment of serious diseases in which signaling by protein
growth factors plays a fundamental role. Scholar Rock is creating a
pipeline of novel product candidates with the potential to
transform the lives of patients suffering from a wide range of
serious diseases, including neuromuscular disorders, cancer,
fibrosis and anemia. Scholar Rock’s approach to targeting the
molecular mechanisms of growth factor activation enabled it to
develop a proprietary platform for the discovery and development of
monoclonal antibodies that locally and selectively target these
signaling proteins at the cellular level. By developing product
candidates that act in the disease microenvironment, the Company
intends to avoid the historical challenges associated with
inhibiting growth factors for therapeutic effect. Scholar Rock
believes its focus on biologically validated growth factors may
facilitate a more efficient development path. For more information,
please visit www.ScholarRock.com or follow Scholar Rock on Twitter
(@ScholarRock) and LinkedIn
(https://www.linkedin.com/company/scholar-rock/).
Scholar Rock® is a registered trademark of Scholar Rock,
Inc.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements regarding the
ability of new directors to influence Scholar Rock’s progress,
Scholar Rock’s ability to develop its pipeline, including its
product candidates, the potential of Scholar Rock’s platform, and
Scholar Rock’s growth expectations. . The use of words such as
“may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,”
“believe,” “estimate,” “project,” “intend,” “future,” “potential,”
or “continue,” and other similar expressions are intended to
identify such forward-looking statements. All such forward-looking
statements are based on management's current expectations of future
events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
These risks and uncertainties include those risks more fully
discussed in the section entitled "Risk Factors" in Scholar Rock’s
Annual Report on Form 10-K for the year ended December 31, 2020, as
well as discussions of potential risks, uncertainties, and other
important factors in Scholar Rock’s subsequent filings with the
Securities and Exchange Commission. Any forward-looking statements
represent Scholar Rock’s views only as of today and should not be
relied upon as representing its views as of any subsequent date.
All information in this press release is as of the date of the
release, and Scholar Rock undertakes no duty to update this
information unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210318005940/en/
Scholar Rock Contact: Investors Catherine Hu
chu@scholarrock.com
Media Contact: Ariane Lovell Finn Partners
ariane.lovell@finnpartners.com 917-565-2204
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Jul 2023 to Jul 2024